Hemab ApS, a new company led by scientists with experience in haemophilia drug development, has been launched in Copenhagen, Denmark to develop bispecific antibodies for treating rare bleeding disorders. The company was incubated by Novo Seeds, the early-stage investment arm of Novo Holdings A/S. The size of the seed funding was not disclosed.
Johan Faber and Søren Bjørn, formerly with Novo Nordisk A/S, are the company’s founders, having previously been involved in research and development for new haemophilia drugs. Mr Faber is also the company’s chief executive officer.